Greenland Mines Ltd. (NASDAQ: GRML) disclosed in a Form 4 filing that Chief Financial Officer Jeff LeBlanc purchased 1.4 million shares of the company’s common stock in open-market transactions. According to the filing, LeBlanc acquired the shares at a price of $0.1752 per share, increasing his direct beneficial ownership to 4,820,342 shares.
The filing states that LeBlanc purchased 626,472 shares on July 16, 2026, and an additional 773,528 shares on July 17, 2026. The transactions were reported in a filing with the U.S. Securities and Exchange Commission on July 17.
Insider purchases are often viewed as a signal of confidence in a company’s future prospects. LeBlanc’s substantial acquisition comes at a time when Greenland Mines is advancing its dual operating divisions: Mining and Biotech. The mining division is focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The biotech division includes Klotho’s KLTO-202 primary indication for ALS.
The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. This dual approach positions Greenland Mines at the intersection of critical mineral supply chains and innovative biotechnology, potentially offering diversified revenue streams and risk mitigation.
LeBlanc’s purchase could be interpreted as a bet on the successful execution of this strategy. The Skaergaard Project is one of the world’s largest undeveloped palladium and gold resources, while the Sarfartoq project targets rare earth elements essential for permanent magnets used in electric vehicles and wind turbines. On the biotech side, KLTO-202 targets ALS, a neurodegenerative disease with significant unmet medical need.
Investors often monitor insider buying as a gauge of management’s belief in the company’s valuation and growth trajectory. With LeBlanc now holding over 4.8 million shares, his financial interests are closely aligned with shareholders. The timing of the purchase, following recent market volatility, may suggest that the CFO views the current share price as undervalued relative to the company’s potential.
For further details, Greenland Mines’ latest news and updates are available in the company’s newsroom at https://ibn.fm/GRML.
